<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28198" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Radioactive Iodine Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Minhthao</given-names>
          </name>
          <aff>University Hospitals Richmond and Bedford Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Minhthao Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28198.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Radioactive iodine therapy is used in the management and treatment of hyperthyroidism. This activity describes the indications, actions, and contraindications of radioactive iodine therapy as a valuable agent in the treatment of hyperthyroidism. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to members of the interprofessional team in the treatment of patients with hyperthyroidism.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of radioactive iodine therapy.</p></list-item><list-item><p>Describe the potential adverse effects involved with radioactive iodine therapy.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving iodine therapy.</p></list-item><list-item><p>Outline some interprofessional team strategies for improving care coordination and communication to advance radioactive iodine therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28198&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28198">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28198.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Radioactive iodine (iodine-131) therapy is indicated for the management of hyperfunctioning thyroid disease and thyroid cancer.<xref ref-type="bibr" rid="article-28198.r1">[1]</xref><xref ref-type="bibr" rid="article-28198.r2">[2]</xref>&#x000a0;It is classified as radioactive nuclear medicine and was first synthesized in 1941, and the FDA approved it in 1971 for its therapeutic use. Its action&#x000a0;causes permanent destruction to the thyroid tissue by emitting radiation of two sorts, gamma and beta rays.<xref ref-type="bibr" rid="article-28198.r3">[3]</xref><xref ref-type="bibr" rid="article-28198.r4">[4]</xref>&#x000a0;Gamma radiation effects are more useful for diagnostic purposes,&#x000a0;whereas beta radiation effects are therapeutic.<xref ref-type="bibr" rid="article-28198.r4">[4]</xref>&#x000a0;Its action is dependant on the uptake of iodine from thyroid tissue and is ineffective in patients who&#x000a0;have a&#x000a0;hyperfunctioning disease without iodine uptake. It is indicated in patients with high surgical risk and decreased life expectancy or patients who have failed to obtain a euthyroid state or can not tolerate oral anti-thyroid agents.&#x000a0;Radioactive iodine therapy may be administered as adjuvant therapy to surgery in patients with thyroid carcinoma and may be given four to six weeks of post-surgery.<xref ref-type="bibr" rid="article-28198.r5">[5]</xref></p>
        <p>
<bold>FDA Approved</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Graves disease</p>
          </list-item>
          <list-item>
            <p>Toxic adenoma</p>
          </list-item>
          <list-item>
            <p>Toxic multinodular goiter</p>
          </list-item>
          <list-item>
            <p>Non-toxic multinodular goiter</p>
          </list-item>
          <list-item>
            <p>Well-differentiated thyroid&#x000a0;carcinoma</p>
          </list-item>
        </list>
        <p>Radioactive iodine diagnostic use can differentiate between the different hyper or hypo-functioning thyroid diseases. This differentiation occurs by measuring the uptake of radioactive iodine in the thyroid after 24-hours.<xref ref-type="bibr" rid="article-28198.r6">[6]</xref></p>
        <p>
<bold>Increased RAIU</bold>
<xref ref-type="bibr" rid="article-28198.r7">[7]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Graves disease</p>
          </list-item>
          <list-item>
            <p>Toxic multinodular goiter</p>
          </list-item>
          <list-item>
            <p>Thyroid adenoma&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Decreased RAIU</bold>
<xref ref-type="bibr" rid="article-28198.r7">[7]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Subacute thyroiditis</p>
          </list-item>
          <list-item>
            <p>Painless thyroiditis</p>
          </list-item>
          <list-item>
            <p>Iodine-induced hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Factitious hyperthyroidism</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28198.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Iodine is a natural precursor for thyroid hormones triiodothyronine (T3) and thyroxine (T4) and is uptaken from the blood into the thyroid follicular cell by the&#x000a0;sodium and iodide transporter. Similarly, radioactive iodine (RAI) exerts its effects once it is taken up by the follicular cells of the thyroid, emitting beta rays that further cause definitive local damage to the thyroid tissue.<xref ref-type="bibr" rid="article-28198.r8">[8]</xref><xref ref-type="bibr" rid="article-28198.r9">[9]</xref></p>
      </sec>
      <sec id="article-28198.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Iodine-131 is available as<xref ref-type="bibr" rid="article-28198.r4">[4]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral gelatine capsules</p>
          </list-item>
          <list-item>
            <p>Oral drinking solution</p>
          </list-item>
          <list-item>
            <p>Intravenous injections</p>
          </list-item>
        </list>
        <p>Hyperthyroid dosage</p>
        <list list-type="bullet">
          <list-item>
            <p>148 to 370 MBq</p>
          </list-item>
        </list>
        <p>Thyroid carcinoma dosage</p>
        <list list-type="bullet">
          <list-item>
            <p>3700 to 5550 MBq</p>
          </list-item>
        </list>
        <p>Medications contradicted before therapy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antithyroid medication (propylthiouracil,&#x000a0;methimazole)</p>
          </list-item>
          <list-item>
            <p>Amiodarone</p>
          </list-item>
          <list-item>
            <p>Contrast agents</p>
          </list-item>
        </list>
        <p>During radioactive iodine therapy, agents containing iodine can hinder&#x000a0;its uptake from the transporter&#x000a0;of thyroid cells, as iodine is a natural precursor for thyroid hormones. All patients should be on an iodine-free diet for seven days and longer for patients receiving therapy for thyroid carcinoma.<xref ref-type="bibr" rid="article-28198.r8">[8]</xref>&#x000a0;Although contraindicated, treatment with antithyroid agent methimazole (MTZ) may be initiated before radioactive iodine therapy in select patients with severe hyperfunctioning thyroid disease or cardiac disease.&#x000a0;Transient thyrotoxicosis may transpire shortly following radioactive iodine therapy due to the leakage of stored triiodothyronine (T3) and thyroxine (T4).<xref ref-type="bibr" rid="article-28198.r8">[8]</xref><xref ref-type="bibr" rid="article-28198.r7">[7]</xref>&#x000a0;Thionomide therapy may&#x000a0;decrease&#x000a0;any storage of thyroid hormones&#x000a0;and&#x000a0;ensure a euthyroid state&#x000a0;to&#x000a0;prevent possible complications of thyrotoxicosis.<xref ref-type="bibr" rid="article-28198.r8">[8]</xref> Methimazole is preferred over propylthiouracil(PTU) as it has a significant failure rate.<xref ref-type="bibr" rid="article-28198.r6">[6]</xref>&#x000a0;If a patient receives ethionamide, the recommendation is to discontinue it three to five days before radioactive iodine therapy.<xref ref-type="bibr" rid="article-28198.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28198.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects range from mild to severe, depending on the dose administered.</p>
        <p>
<bold>Early Complications</bold>
<xref ref-type="bibr" rid="article-28198.r2">[2]</xref>
<xref ref-type="bibr" rid="article-28198.r5">[5]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Chest Pain</p>
          </list-item>
          <list-item>
            <p>Pruritis</p>
          </list-item>
          <list-item>
            <p>Hives</p>
          </list-item>
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Teratogenicity</p>
          </list-item>
          <list-item>
            <p>Bone marrow suppression</p>
          </list-item>
          <list-item>
            <p>Radiation thyroiditis</p>
          </list-item>
          <list-item>
            <p>Sialadenitis/xerostomia</p>
          </list-item>
          <list-item>
            <p>Gonadal damage/Infertility</p>
          </list-item>
          <list-item>
            <p>Dry eye</p>
          </list-item>
          <list-item>
            <p>Nasolacrimal duct obstruction</p>
          </list-item>
          <list-item>
            <p>Transient thyrotoxicosis</p>
          </list-item>
          <list-item>
            <p>Pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Brain edema</p>
          </list-item>
        </list>
        <p>
<bold>Late Complications</bold>
<xref ref-type="bibr" rid="article-28198.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone marrow depression</p>
          </list-item>
          <list-item>
            <p>Leukemia</p>
          </list-item>
          <list-item>
            <p>Stomach Cancer</p>
          </list-item>
          <list-item>
            <p>Bladder Cancer</p>
          </list-item>
          <list-item>
            <p>Breast Cancer</p>
          </list-item>
          <list-item>
            <p>Pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Permanent bone marrow suppression</p>
          </list-item>
          <list-item>
            <p>Genetic effects</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
        </list>
        <p>The recommendation for patients who have preexisting ophthalmopathy is to have treatment with oral prednisone therapy to prevent exacerbations. Treatment can be started a few days after RAI therapy and should continue for 1 to 3 months.<xref ref-type="bibr" rid="article-28198.r6">[6]</xref><xref ref-type="bibr" rid="article-28198.r10">[10]</xref>&#x000a0;The damage to thyroid tissue during radioactive iodine therapy can release thyroid antigens, which may travel to the TSH autoantibodies located in the orbital, causing inflammatory and osmotic effects.<xref ref-type="bibr" rid="article-28198.r11">[11]</xref>&#x000a0;Treatment with RAI may predispose patients to permanent hypothyroidism as it causes definitive destruction of thyroid tissue. Patients may require lifelong thyroxine therapy.<xref ref-type="bibr" rid="article-28198.r7">[7]</xref></p>
      </sec>
      <sec id="article-28198.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Radioactive iodine therapy (RAI) is contraindicated in the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Breastfeeding</p>
          </list-item>
          <list-item>
            <p>Carcinoma with no iodine uptake</p>
          </list-item>
          <list-item>
            <p>Graves ophthalmopathy (moderate to severe)</p>
          </list-item>
          <list-item>
            <p>Severe thyrotoxicosis</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
        </list>
        <p>The radioactive substance can pass through the placenta and&#x000a0;may cause&#x000a0;definitive thyroid damage and irreversible mental retardation to the developing fetus. Contraceptive use is a strong recommendation to females of childbearing age who are planning radioactive iodine therapy. A negative pregnancy test should be a consideration before initiating therapy as pregnancy and breastfeeding are absolute contraindications.<xref ref-type="bibr" rid="article-28198.r7">[7]</xref><xref ref-type="bibr" rid="article-28198.r10">[10]</xref></p>
      </sec>
      <sec id="article-28198.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring and routine checkups are lifelong for patients following RAI therapy. Thyroid function tests are to be observed every 4-6 weeks for six months&#x000a0;until&#x000a0;the patient achieves a euthyroid or hypothyroid state. Free Thyroxine levels should be monitored routinely after treatment, as TSH levels can remain low for an extended duration despite the patient being clinically euthyroid. TFT&#x000a0;can be monitored at six to twelve-month periods after achieving the treatment outcome. If treatment failure is suspected, and the patient is still in a hyperthyroid state six months post-therapy, the clinician may reconsider RAI&#x000a0;retreatment.<xref ref-type="bibr" rid="article-28198.r6">[6]</xref></p>
      </sec>
      <sec id="article-28198.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>Radiation-induced toxicity</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity reactions</p>
          </list-item>
          <list-item>
            <p>Radiation-induced thyroiditis</p>
          </list-item>
        </list>
        <p>Potassium iodide(KI) effectively blocks radioactive iodine uptake in the thyroid and can be helpful during toxicity.<xref ref-type="bibr" rid="article-28198.r12">[12]</xref><xref ref-type="bibr" rid="article-28198.r13">[13]</xref>&#x000a0;RAI, once administered, has rapid absorption through the gastrointestinal tract and is spread to the thyroidal tissue via the bloodstream. RAI excretion is mainly within the kidneys. Patients with renal dysfunction are at risk of decreased clearance and increased levels of RAI and toxicity.<xref ref-type="bibr" rid="article-28198.r14">[14]</xref>&#x000a0;Precautions should be advised to patients post-RAI therapy, as radiation may be harmful around others. Clinical staff must particularly take measures to avoid contact and exposure around women during pregnancy and children.<xref ref-type="bibr" rid="article-28198.r6">[6]</xref></p>
      </sec>
      <sec id="article-28198.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Radioactive iodine therapy(RAI) is a nuclear agent that is FDA-approved and indicated for hyperfunctioning thyroid disease and thyroid carcinoma. This agent's use should be under the management under the supervision of an interprofessional team, including an endocrinologist, a primary care clinician, nurses, and pharmacists. Thorough follow-up and communication between the primary care clinician and specialists are vital to monitor free T4 and TSH levels to gauge the success or complications of treatment. Providers involved in the patients' direct care, such as nurses, should be familiar with the clinical signs and symptoms of treatment complications such as thyroid storm, ophthalmopathy, and transient hypothyroidism. Consultation with an ophthalmologist may be necessary for patients suffering from&#x000a0;thyroid-associated&#x000a0;orbitopathy.</p>
        <p>Counseling and discontinuation of treatment are strongly advised during pregnancy. A negative pregnancy test should be considered before therapy, as radioactive iodine can readily cross the placenta and be taken up by the fetus, further causing irreversible damage. Select patients should be educated on pre-treatment if needed, and all patients should receive counsel about iodine restriction before therapy. Patients should receive clear instructions&#x000a0;regarding radiation toxicity and avoidance of household contacts, pregnant women, and children. The interprofessional team should also counsel patients on the adverse effects of therapy, and the early and late complications that may arise, and the severity of the complications.</p>
      </sec>
      <sec id="article-28198.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28198&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28198">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28198/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28198">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28198.s11">
        <title>References</title>
        <ref id="article-28198.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Radioactive iodine therapy.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>420</fpage>
            <page-range>420-8</page-range>
            <pub-id pub-id-type="pmid">22914564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fard-Esfahani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emami-Ardekani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fallahi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fard-Esfahani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Beiki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hassanzadeh-Rad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eftekhari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma.</article-title>
            <source>Nucl Med Commun</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>808</fpage>
            <page-range>808-17</page-range>
            <pub-id pub-id-type="pmid">24751702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawin</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Radioiodine and the treatment of hyperthyroidism: the early history.</article-title>
            <source>Thyroid</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-76</page-range>
            <pub-id pub-id-type="pmid">9133679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wyszomirska</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Iodine-131 for therapy of thyroid diseases. Physical and biological basis.</article-title>
            <source>Nucl Med Rev Cent East Eur</source>
            <year>2012</year>
            <month>Aug</month>
            <day>28</day>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-3</page-range>
            <pub-id pub-id-type="pmid">22936505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Limaiem</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anastasopoulou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mazzoni</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title>Papillary Thyroid Carcinoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30725628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pokhrel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bhusal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Graves Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">28846288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mathew</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperthyroidism</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30725738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mumtaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Mohd Khir</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Radioiodine I-131 for the therapy of graves' disease.</article-title>
            <source>Malays J Med Sci</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">22589645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ganie</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Iodine, Iodine metabolism and Iodine deficiency disorders revisited.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-7</page-range>
            <pub-id pub-id-type="pmid">21448409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fox</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Anastasopoulou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <chapter-title>Graves Orbitopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">31751079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tanda</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Manetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dell'Unto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rocchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barbesino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pinchera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Graves' ophthalmopathy and 131I therapy.</article-title>
            <source>Q J Nucl Med</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-12</page-range>
            <pub-id pub-id-type="pmid">10731781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reiners</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Potassium iodide (KI) to block the thyroid from exposure to I-131: current questions and answers to be discussed.</article-title>
            <source>Radiat Environ Biophys</source>
            <year>2013</year>
            <month>May</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-93</page-range>
            <pub-id pub-id-type="pmid">23475155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Zanzonico</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use.</article-title>
            <source>Thyroid</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-7</page-range>
            <pub-id pub-id-type="pmid">9133683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28198.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mozzor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chugh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buddharaju</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schwarcz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valiquette</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dosing of radioactive iodine in end-stage renal disease patient with thyroid cancer.</article-title>
            <source>Endocrinol Diabetes Metab Case Rep</source>
            <year>2017</year>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">29158901</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
